- Home
- BLX vs TSHA Comparison
BLX vs TSHA Comparison
Compare BLX & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BLX | TSHA |
|---|---|---|
| Founded | 1977 | 2019 |
| Country | Panama | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 1997 | 2020 |
Fundamental Metrics
Financial Performance| Metric | BLX | TSHA |
|---|---|---|
| Price | $54.90 | $3.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $65.90 | $13.00 |
| AVG Volume (30 Days) | 124.2K | ★ 3.8M |
| Earning Date | 10-26-2026 | 11-03-2026 |
| Dividend Yield | ★ 4.97% | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,773,000.00 |
| Revenue This Year | $10.52 | N/A |
| Revenue Next Year | $10.12 | $1,023.00 |
| P/E Ratio | $8.26 | ★ N/A |
| Revenue Growth | N/A | ★ 17.28 |
| 52 Week Low | $38.41 | $3.46 |
| 52 Week High | $63.20 | $7.30 |
Technical Indicators
Market Signals| Indicator | BLX | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 46.37 | 35.11 |
| Support Level | $54.32 | $3.46 |
| Resistance Level | $56.04 | $4.72 |
| Average True Range (ATR) | 1.15 | 0.27 |
| MACD | 0.05 | 0.03 |
| Stochastic Oscillator | 34.77 | 31.84 |
Price Performance
Historical ComparisonAbout BLX Banco Latinoamericano de Comercio Exterior S.A.
Bladex Inc is a Panama-based bank focused on providing financial solutions to financial institutions and corporations throughout Panama.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.